Table 3.
Frequency of resistance to commonly used nucleoside and non‐nucleoside reverse transcriptase inhibitors (NRTI and NNRTI)
| Antiretroviral drugs | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| NRTI | NNRTI | ||||||||
| ARV | ABC | AZT | FTC | 3TC | TDF | EFV | NVP | RPV | DOR |
| Susceptible | 466 | 468 | 466 | 466 | 469 | 426 | 418 | 448 | 441 |
| Resistant | 4 | 2 | 4 | 4 | 1 | 44 | 52 | 22 | 29 |
| Overall % Resistance (95% CI) | 0.9 (0.2 to 2.2) | 0.5 (0.1 to 1.5) | 0.9 (0.2 to 2.2) | 0.9 (0.2 to 2.1) | 0.2 (0.0 to 1.2) | 10.0 (6.9 to 12.4) | 12.0 (8.4 to 14.3) | 5.0 (2.0 to 7.01) | 6.2 (4.2 to 8.7) |
ABC, abacavir; AZT, azidothymidine; FTC, emtricitabine; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; EFV, efavirenz; NVP, nevirapine; RPV, rilpivirine; DOR, doravirine.